NASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis $12.36 -0.14 (-1.12%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Stoke Therapeutics Stock (NASDAQ:STOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Stoke Therapeutics alerts:Sign Up Key Stats Today's Range$12.26▼$12.4450-Day Range$11.40▼$15.9252-Week Range$3.46▼$17.58Volume539,249 shsAverage Volume766,677 shsMarket Capitalization$644.22 millionP/E RatioN/ADividend YieldN/APrice Target$20.83Consensus RatingBuy Company OverviewStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Read More… Banking failure dead ahead (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Stoke Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks77th Percentile Overall ScoreSTOK MarketRank™: Stoke Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 275th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingStoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageStoke Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Stoke Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.10) to ($2.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stoke Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.03% of the outstanding shares of Stoke Therapeutics have been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.59 Percentage of Shares Shorted13.03% of the outstanding shares of Stoke Therapeutics have been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment1.37 News SentimentStoke Therapeutics has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Stoke Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 4 people have searched for STOK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,221,875.00 in company stock.Percentage Held by Insiders11.30% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Stoke Therapeutics' insider trading history. Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Stock News HeadlinesStoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Consensus Price Target from BrokeragesOctober 26, 2024 | americanbankingnews.comStoke Therapeutics assumed with an Outperform at LeerinkOctober 13, 2024 | finance.yahoo.comBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonOctober 31, 2024 | Porter & Company (Ad)Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic DiseasesOctober 12, 2024 | msn.comThe story of Stoke City’s shrinking pitch and how Arsene Wenger fought to get it changedOctober 12, 2024 | msn.comWarning to illegal Stoke-on-Trent drivers as new police team hit the streetsOctober 12, 2024 | msn.comWhy I'm confident Stoke City will score enough goals in new regime thanks to key changeOctober 12, 2024 | msn.comStoke Therapeutics (NASDAQ:STOK) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comSee More Headlines STOK Stock Analysis - Frequently Asked Questions How have STOK shares performed this year? Stoke Therapeutics' stock was trading at $5.26 at the beginning of 2024. Since then, STOK stock has increased by 135.0% and is now trading at $12.36. View the best growth stocks for 2024 here. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.11. The company had revenue of $4.83 million for the quarter, compared to analysts' expectations of $3.33 million. Stoke Therapeutics had a negative trailing twelve-month return on equity of 57.89% and a negative net margin of 683.35%. When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Stoke Therapeutics' major shareholders? Stoke Therapeutics' top institutional shareholders include Skorpios Trust (16.92%), Assenagon Asset Management S.A. (2.49%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Skorpios Trust, Stephen J Tulipano, Jonathan Allan, Barry Ticho and Huw M Nash. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings8/07/2024Today10/31/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STOK CUSIPN/A CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$20.83 High Stock Price Target$35.00 Low Stock Price Target$13.00 Potential Upside/Downside+68.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,700,000.00 Net Margins-683.35% Pretax Margin-683.35% Return on Equity-57.89% Return on Assets-42.22% Debt Debt-to-Equity RatioN/A Current Ratio6.67 Quick Ratio6.67 Sales & Book Value Annual Sales$15.16 million Price / Sales42.57 Cash FlowN/A Price / Cash FlowN/A Book Value$3.57 per share Price / Book3.47Miscellaneous Outstanding Shares52,121,000Free Float46,699,000Market Cap$645.26 million OptionableOptionable Beta0.97 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:STOK) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.